Hospira Recalls Marcaine Injection Vials Due to Metal Particulate Matter
Hospira is recalling 40,360 vials of Marcaine (bupivacaine hydrochloride) injection because some units contain visible metal particles that discolor the solution.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class I, which indicates a reasonable probability that use of the product will cause serious adverse health consequences or death. The presence of metal particulate matter in an injectable drug poses a significant risk of injury.
Plain-English summary
Hospira, Inc. is recalling 40,360 vials of Marcaine (bupivacaine hydrochloride) injection, USP, 0.25%, 30 mL single-dose vials. The affected product is preservative-free, packaged in 10-count vials per carton, and is available by prescription only. The specific lot number is 25-220-DD, with an expiration date of January 2015.
The recall was initiated because units of this lot may contain visible metal particles embedded in the vial and in the solution, which causes the product to be discolored. The product was distributed nationwide.
Healthcare providers and patients should check their inventory for this specific lot number and expiration date. If the product is found, it should be quarantined and not used. Consumers should contact their healthcare provider for guidance on alternative treatments or further instructions.
The recalled product
- Product
- MARCAINE (BUPIVACAINE HYDROCHLORIDE)
- Brand
- MARCAINE
- Manufacturer
- Hospira Inc.
- Category
- Drug — Injectable Anesthetic
- Affected units
- 40,360
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 25-220-DD
- Exp 1JAN2015
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · MARCAINE
- SevereHospira Recalls Marcaine Injection Vials Due to Sterility and Potency Defects
FDA (Drugs) · 2016-10-19
- SevereHospira Recalls Marcaine Injection Due to Sterility and Potency Issues
FDA (Drugs) · 2016-10-19
- SevereHospira Recalls Marcaine Injection Vials Due to Visible Metal Particles
FDA (Drugs) · 2014-10-08
- CriticalHospira Recalls Marcaine Injection Vials Due to Visible Metal Particles
FDA (Drugs) · 2014-06-11
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26